NCT00261053已完成2 期
A Phase II Exploratory, Open-label Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Primary outcomes: Relief of angioedema symptoms
研究概览
简要总结
The purpose of this single-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Other
Open-label i.v. administration of 100 U/kg rhC1INH
干预措施: i.v. recombinant human C1 inhibitor (Drug)
结局指标
主要结局
Primary outcomes: Relief of angioedema symptoms
次要结局
- Secondary outcomes: Safety and tolerability; pharmacokinetics/pharmacodynamics
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)MZLNCT03797456Beijing InnoCare Pharma Tech Co., Ltd.111
已完成
2 期
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)Non-Hodgkin's LymphomaNCT00517049Genentech, Inc.49
已完成
1 期
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)Mantle Cell LymphomaNCT03494179Beijing InnoCare Pharma Tech Co., Ltd.106
进行中（未招募）
2 期
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Non-Small Cell Lung CancerNCT06606847AstraZeneca30
撤回
2 期
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic MutationRefractory Follicular LymphomaFollicular LymphomaNCT06068881Epizyme, Inc.55